OBJECTIVE: To investigate the diagnostic value of serum @entity442 ( @entity442 ) and @entity2301 ( @entity2301 ) measurements in adult @entity1 with @entity2012 and @entity2338 ( @entity2338 ). METHODS: Serum @entity442 and @entity2301 levels were measured in 39 active acromegalic @entity1 , 34 adult @entity1 with @entity2338 and 150 healthy adults. Disease activity in @entity1 with @entity2012 was confirmed by nadir GH levels during an oral @entity413 tolerance test (OGTT). Among @entity1 with @entity2012 , 15 had not been treated previously and 24 had been treated but not cured. @entity2338 in adults was diagnosed by an insulin tolerance test (ITT). Among @entity1 with @entity2338 , 15 were aged 20-40 years (9 @entity1 and 6 @entity1 ) and 19 were aged over 40 years (9 @entity1 and 10 @entity1 ). One hundred and fifty healthy subjects were recruited as a control group. To compare the individual serum @entity442 and @entity2301 levels of @entity1 with the results of the gold standard, we calculated age- and sex-corrected standard deviation scores ( @entity214 ) for individual @entity442 and @entity2301 levels. The sensitivities of serum @entity442 and @entity2301 measurements for the disease diagnosis were analyzed using the mean +/- 2 SD of the values of healthy control subjects as a diagnostic cutoff, defining 95% specificity. RESULTS: The mean @entity442 and @entity2301 @entity214 levels were significantly higher in active acromegalic @entity1 , both untreated and treated but not cured, than in the control subjects (p < 0.05). The sensitivities of serum @entity442 and @entity2301 measurements for the diagnosis of @entity2012 were 97.4 and 81.8%, respectively. In untreated @entity1 with @entity2012 , the sensitivities of serum @entity442 and @entity2301 measurements for the diagnosis of disease were 100 and 100%, while these were 95.8 and 72.7% in treated @entity1 with @entity2012 . In adult @entity1 with @entity2338 , the mean @entity442 and @entity2301 @entity214 were significantly lower than those of the control subjects ( @entity442 , -2.2 +/- 0.8 vs. 0.0 +/- 1.0 @entity214 , p < 0.0001); @entity2301 , -1.7 +/- 1.2 vs. 0.0 +/- 1.0 @entity214 , p < 0.0001), but there was a considerable overlap between @entity2338 in adults and the controls. In all @entity1 with @entity2338 , the sensitivities of serum @entity442 and @entity2301 measurements were 64.7 and 52.9%, respectively. In the group of @entity1 aged 20-40 years, the sensitivity of @entity442 measurement for the diagnosis of @entity2338 was 100%, although the number of @entity1 was only 6. CONCLUSION: Both serum @entity442 and @entity2301 measurements are comparable to an oral @entity413 tolerance test in @entity1 with untreated @entity2012 , but in acromegalic @entity1 that have undergone surgery and/or radiotherapy, serum @entity442 is more valuable for determining disease activity than serum @entity2301 . Serum @entity442 and @entity2301 measurements are not valuable for the diagnosis of @entity2338 in adults, but in @entity1 aged 20-40 years serum @entity442 measurement appears to be useful in the diagnosis of @entity2338 .

Diagnostic value of serum @entity442 and XXXX in growth hormone disorders in adults.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity2338 :: ('MESH:D004393', 'Disease') :: ['GHD', 'GH deficiency'] @entity2301 :: ('3486', 'Gene') :: ['IGFBP-3', 'insulin-like growth factor-binding protein-3'] @entity442 :: ('3479', 'Gene') :: ['insulin-like growth factor-I', 'IGF-I'] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity214 :: ('CHEBI:8984', 'Chemical') :: ['SDS']
@entity2301 :: (3486,Gene) :: ['IGFBP-3']
